Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Trial Profile

A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANB 019 (Primary) ; ANB 019 (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GALLOP
  • Sponsors AnaptysBio
  • Most Recent Events

    • 30 Sep 2019 According to an AnaptysBio media release, based on the interim results the company is curtailing the washout period required prior to enrollment. Additional data form the trial is expeted during 2020.
    • 30 Sep 2019 Interim results presented in the AnaptysBio media release.
    • 08 Nov 2018 According to an AnaptysBio media release, data from this study is expected in mid 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top